Clinical Trial Detail

NCT ID NCT02414269
Title Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

lung non-small cell carcinoma

breast cancer

malignant pleural mesothelioma

Therapies

Cyclophosphamide + iCasp9M28z T cells

iCasp9M28z T cells

Age Groups: adult senior

No variant requirements are available.